XPro1595 + Placebo
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Cognitive Impairment (MCI)
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders
Trial Timeline
Jun 1, 2023 → Oct 26, 2023
NCT ID
NCT05321498About XPro1595 + Placebo
XPro1595 + Placebo is a phase 2 stage product being developed by INmune Bio for Mild Cognitive Impairment (MCI). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05321498. Target conditions include Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05321498 | Phase 2 | Withdrawn |
| NCT05318976 | Phase 2 | Completed |
Competing Products
20 competing products in Mild Cognitive Impairment (MCI)